



The autotransporter protein from *Bordetella avium*, Baa1, is involved in host cell attachment

S.B. Stockwell^{a,*}, H. Kuzmiak-Ngiam^b, N.M. Beach^{a,1}, D. Miyamoto^c, R. Fernandez^d, L. Temple^a

^a Department of Integrated Science and Technology, James Madison University, Harrisonburg, VA 22807, United States

^b Department of Biochemistry & Biophysics, University of Rochester, Rochester, NY 14627, United States

^c Department of Biology, Drew University, Madison, NJ 07940, United States

^d Department of Microbiology and Immunology, Life Sciences Center, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada

ARTICLE INFO

Article history:

Received 11 March 2011

Received in revised form 21 April 2011

Accepted 27 April 2011

Keywords:

Bordetella avium

Autotransporter

Attachment

Adhesin

ABSTRACT

Bordetella avium is a Gram negative upper respiratory tract pathogen of birds. *B. avium* infection of commercially raised turkeys is an agriculturally significant problem. Here we describe the functional analysis of the first characterized *B. avium* autotransporter protein, Baa1. Autotransporters comprise a large family of proteins found in all groups of Gram negative bacteria. Although not unique to pathogenic bacteria, autotransporters have been shown to perform a variety of functions implicated in virulence. To test the hypothesis that Baa1 is a *B. avium* virulence factor, unmarked *baa1* deletion mutants ($\Delta baa1$) were created and tested phenotypically. It was found that *baa1* mutants have wild-type levels of serum sensitivity and infectivity, yet significantly lower levels of turkey tracheal cell attachment *in vitro*. Likewise, semi-purified recombinant His-tagged Baa1, expressed in *Escherichia coli*, was shown to bind specifically to turkey tracheal cells via western blot analysis. Taken together, we conclude that Baa1 acts as a host cell attachment factor and thus plays a role *B. avium* virulence.

Published by Elsevier GmbH.

Introduction

Autotransporters comprise a large family of secreted proteins that use the Type V secretion system which is conserved among all major groups of Gram negative bacteria (reviewed in Henderson et al. 2004; Hayes et al. 2010; Dautin and Bernstein 2007). Autotransporters are modular proteins consisting of an N-terminal signal sequence for targeting to the Sec apparatus, a C-terminal beta-barrel domain for targeting to the outer membrane, and a passenger domain that is exposed to the bacterial surface (reviewed in Dautin and Bernstein 2007; Henderson et al. 2004). The beta-barrel domain facilitates the translocation of the N-terminal passenger domain through the outer membrane, although the mechanism of this translocation is under debate (reviewed in Dautin and Bernstein 2007). In some cases, the passenger domain is cleaved via autoproteolysis and thus released from the cell surface (Dautin et al. 2007; Yen et al. 2008). While the transport domains of autotransporters are structurally and functionally conserved, differences within surface exposed or released N-terminal passenger domains allow for the diversity of autotransporter protein function.

Although not unique to pathogenic bacteria, autotransporters have been found to perform a variety of virulence-related functions in Gram negative pathogens. Functions include those such as protein/lipid degradation (e.g. *Moraxella catarrhalis* McaP (Timpe et al. 2003)), serum resistance (e.g. *Bordetella pertussis* BrkA (Fernandez and Weiss 1994), *Yersinia pestis* YadA (El Tahir and Skurnik 2001)), host actin polymerization (e.g. *Shigella flexneri* IcsA (Sansone et al. 1991)), as well as attachment to host tissues (e.g. *Escherichia coli* AIDA-1 (Sherlock et al. 2004), *Y. pestis* YadA (El Tahir and Skurnik 2001), and *B. pertussis* Pertactin (Sansone et al. 1991) and BrkA (Weingart and Weiss 2000)). Surface localization and high antigenicity of these virulence factor proteins make them ideal candidates for inclusion in subunit vaccines. For instance, *B. pertussis* Pertactin is an important component of the current whooping cough subunit vaccine.

Bordetella avium causes a disease of birds called bordetellosis (i.e. turkey coryza; Jackwood and Saif 2008), with similarities to whooping cough in humans. Current antibiotic treatments and live-attenuated vaccines have proven ineffective in controlling this pathogen within commercial poultry flocks. Upon respiratory introduction, *B. avium* specifically attaches to and colonizes ciliated tracheal cells of infected birds. In doing so, ciliary cells are effaced and poults demonstrate upper respiratory tract symptoms including profuse nasal and ocular discharge in addition to signature sneezing/coughing called “snicking.” Although usually non-fatal, *B. avium* infection of commercial flocks leads to significant economic

* Corresponding author. Tel.: +1 540 568 8980.

E-mail address: stockwsb@jmu.edu (S.B. Stockwell).

¹ Current address: Virginia Polytechnic Institute and State University, Blacksburg, VA, United States.

Table 1
Strains used in this study.

| Strain or plasmid | Relevant genotype/description | Source/Reference |
|---|---|-----------------------------|
| <i>B. avium</i> 197 N | Wild type parental <i>B. avium</i> strain | Temple et al. (1998) |
| $\Delta baa1$ | Unmarked <i>baa1</i> deletion mutant | This work |
| <i>E. coli</i> DH5 α | Cloning strain | Invitrogen (Carlsbad, CA) |
| Top10F' | Cloning strain | |
| MC4100 λ pir | Conjugation donor strain | Hoffmann et al. (1998) |
| BL21(DE3) | Expression strain | Invitrogen (Carlsbad, CA) |
| Plasmids | | |
| pBluescript (pSK-) | 3.0 kb cloning plasmid, Amp ^R | Stratagene (La Jolla, CA) |
| pET30b | 5.4 kb expression plasmid, Kan ^R , T7/lac inducible promoter, N-terminal 6 \times HIS | Stratagene (La Jolla, CA) |
| pKAS46 | <i>B. avium</i> suicide plasmid. oriR6K oriT rpsL Amp ^R Kan ^R | Skorupski and Taylor (1996) |
| pRK2103 | <i>E. coli</i> conjugation helper plasmid, Kan ^R | |
| pSK(-)(<i>baa1</i>) | Full-length <i>baa1</i> ORF cloned into the BamHI/EcoRI sites of pBluescript(-) | This work |
| pSK(-)($\Delta baa1$) | <i>baa1</i> deletion allele at the BamHI/EcoRI sites of pBluescript(-) | This work |
| pKAS46($\Delta baa1$) | <i>baa1</i> deletion allele at the KpnI/SacI sites of pKAS46 | This work |
| pET30b(<i>baa1</i> -pass) | pET30b containing <i>baa1</i> -pass (1777 bp) | This work |
| | Downstream of the T7/lac inducible promoter, Kan ^R | |
| p Ω - <i>hagA</i> _{his} | Qiagen His-tag expression plasmid, pQE30, containing <i>B. avium</i> <i>hagA</i> , Amp ^R | Temple et al. (2010) |

losses due to increased secondary infection prevalence and slow growth rates.

Using a bioinformatics approach to search for novel *B. avium* virulence factors, four ORFs with significant sequence similarity to known autotransporter proteins have been identified (Sebaihia et al. 2006). The passenger domain of one of these putative *B. avium* autotransporter proteins, Baa1 (*B. avium* autotransporter 1), shows sequence similarity (28% ID, 48% sim. at the amino acid level) to the known *E. coli* tissue adhesin autotransporter, AIDA-1 (Sherlock et al. 2004). Based on this finding, we hypothesized that Baa1 is involved in *B. avium* host attachment. To test this hypothesis, a *baa1* deletion mutant ($\Delta baa1$) and cloned recombinant Baa1 passenger domain (Baa1-Pass) were assayed for their ability to specifically bind to turkey tracheal cells.

Materials and methods

Bacterial strains, plasmids, and growth conditions

The strains used in this study are described in Table 1. *E. coli* and *B. avium* strains were routinely grown in rich media (i.e. Luria-Bertani (LB) or brain-heart infusion (BHI)) at 37 °C. Prior to turkey tracheal attachment assays, *B. avium* cells were grown on Bordet Gengou (BG) agar supplemented with 15% defibrinated sheep's blood. Antibiotics were added where appropriate, at the following concentrations: ampicillin (100 μ g/ml); chloramphenicol (30 μ g/ml); kanamycin (30 μ g/ml for *E. coli*, 100 μ g/ml for *B. avium*).

Restriction enzymes were purchased from New England Biolabs (Ipswich, MA). Primer synthesis and DNA sequencing were performed by Elim Biopharmaceuticals (Hayward, CA). Advantage GC cDNA Polymerase (Clontech, Mountain View, CA) was used in all PCR amplifications.

Construction of the $\Delta baa1$ mutant

Full-length *baa1* ORF was PCR amplified from *B. avium* 197 N chromosomal DNA with restriction enzyme site engineered primers (Forward P1, Reverse P2; see Table 2) using the following reaction conditions: 94 °C for 6 min, followed by 25 cycles of 94 °C for 30 s, 65.5 °C for 30 s, and 68 °C for 3.5 min, finishing with 68 °C for 7 min. The resulting ~2800 bp product was digested with BamHI and EcoRI and ligated into the similarly cut pBluescript(-) plasmid (Stratagene, La Jolla, CA). The ligation mixture was introduced into Top10F' *E. coli* cells (Invitrogen, Carlsbad, CA) via heat shock,

and transformed clones were selected and screened. To create an ~2000 bp deletion within the *baa1* coding region, long range PCR was performed on pSK(*baa1*). Specifically, primers were designed to amplify out of the *baa1* ORF and around the plasmid backbone (Forward P3, Reverse P4; see Table 2). In doing so, only 400 bp on each end of the *baa1* ORF was maintained. Long range PCR was performed as follows: 94 °C for 2 min, followed by 25 cycles of 94 °C for 30 s, 63 °C for 30 s, and 68 °C for 4 min, finishing with 68 °C for 7 min. The ~3.8 kb amplicon was blunted, self-ligated, and transformed into Top10F' *E. coli* cells. Recombinant plasmids containing the *baa1* deletion allele were confirmed by restriction enzyme digestion and sequence analysis. The *baa1* mutant allele was released from pBluescript with KpnI and SacI digestion and ligated into similarly cut allelic exchange vector, pKAS46. The recombinant pKAS46($\Delta baa1$) plasmids were selected for in MC4100 λ pir *E. coli* cells.

The $\Delta baa1$ allele (Fig. 1) was introduced into *B. avium* via homologous recombination. A tri-parental mating was performed between MC4100 λ pir/pKAS($\Delta baa1$), DH5 α /pRK2103, and parental *B. avium* 197 N cells, as previously described (Temple et al. 2010). Two $\Delta baa1$ isolates were obtained independently and confirmed by PCR and sequencing. These strains were used in all further studies.

Construction and induction of the Baa1-Pass-HIS construct

A 1777 bp *baa1* fragment encoding the putative Baa1 passenger domain (Fig. 1) was PCR amplified from *B. avium* 197 N chromosomal DNA with restriction enzyme site engineered primers (Forward P5, Reverse P6; see Table 2) using the following reaction conditions: 94 °C for 6 min, followed by 25 cycles of 94 °C for 2 min, 62 °C for 30 s, and 68 °C for 2 min, finishing with 68 °C for 7 min. The resulting *baa1*-pass amplicon, flanked with 5' EcoRI and 3' XhoI sites was directionally cloned into similarly cut pBluescript (pSK-, Stratagene, La Jolla, CA) and introduced into DH5 α *E. coli* cells

Table 2
Primers used in this study.

| Primer | Sequence (5'→3') ^a |
|--------|----------------------------------|
| P1 | TGGATCCATCAACCCGCGAGAAAG |
| P2 | AGAATTCATGCTGTGCTGATCTTC |
| P3 | TACCAGGCCACGGTTGG |
| P4 | CCGGCCATTGGTGAAGGT |
| P5 | TTGAATTCCTGATCTTGGCCTTGACCTG |
| P6 | ATCTCGAGGAGGGGCTCATCCGGCTGGTATTG |

^a Underlined sequences indicate engineered restriction enzyme sites.

Download English Version:

<https://daneshyari.com/en/article/2092637>

Download Persian Version:

<https://daneshyari.com/article/2092637>

[Daneshyari.com](https://daneshyari.com)